Journal of Positive Psychology & Wellbeing
2022, Vol. 6, No. 4, 461-466

http://journalppw.com
ISSN 2587-0130

An Overview Of Antidote For Midazolam Overdose, Role Of Clinical Laboratory, Anesthesia And Nursing In The Management

Fares Ali Alshahrani[1], Amjad Mousa Almutairi[2], Shaker Bandar Almutairi[2], Zuhair Aesh Awdah Aldadi[3], Eida Habeeb Alshammeri RnMsn[4], Laila Mohammad Alrashidi RnMsn[4], Aydah Habib Alshammry Rn[5], Abbas Ali Al Alasi[6], Omnia Ebraheem Al Saleem[7], Hind Abdulaziz Alshahri [8], Hager Mohammed Ahmad[9], Fatima Ahmed Alqarni[10], Nedaa Jafar Alkhamis [11], Manar Saeed Saad Bin Aboud[12], Meshari Hameed Hamed Alosaimi[13], Hadiah Mohaimeed Awadh Alrashdi[14]

Laboratory Technician, Medical Center, Facilities Security Forces Training Institute in The Riyadh Region, Facilities, Security Forces, Ministry of Interior[1]
Specialist-Nursing, Medical Center, Facilities Security Forces Training Institute in The Riyadh Region, Facilities Security Forces, Ministry of Interior[2]
Alkhurmh General Hospital, Anesthesia Specialist Non Doctor[3]
Maternity And Childrins Hospital, Nursing Specialist[4]
Executive Administration of Nursing Hail Health Cluster, Nursing Technicia[5]
Technician-Nursing, Eradah Complex for Mental Health and Addiction in Jeddah[6]
Phc Al Shifa, Nurse[7]
Nursing Technician, Al Izdihar Phc[8]
Alnoamiy, Nurse, Eradh Complex for Mental Health Jeddah[9]
Nurse, Eradh Complex for Mental Health Jeddah10
Dammam Medical complex, Nursing, Performance Improvment Specialist[11]
Medical Laboratory Specialist, Maternity and Children's Hospital in Al-Kharj[12]
Nursing And Midwifery, Almansour Phc[13]
Technincian -Midwifery and Nursing, Alnakheel Primary Health Care Center- Buraydah[14]

Abstract

Midazolam is commonly administered as a premedication due to its beneficial properties of inducing amnesia, reducing anxiety, and promoting sedation. Incorrect administration of midazolam at an inappropriate dosage elevates the likelihood of respiratory and circulatory depression. An individual died as a consequence of receiving a 10 mg dosage of intravenous (IV) midazolam during an endoscopic procedure.1 While there is no documented evidence of fatalities resulting from the intramuscular (IM) administration of midazolam, we have encountered two instances of excessive doses of IM midazolam being delivered. Thankfully, there were no issues. However, the occurrences highlighted the reality that certain doctors and nurses may lack the necessary expertise in administering a drug, even if it has been widely used for an extended period of time. Only a few examples have been recorded in the literature where the premedication of IM midazolam was administered at a dosage four times higher than recommended. The sedative effects were extended, however, there was no occurrence of circulatory or respiratory depression, which is fortunate. Both accidents occurred due to the nurse and resident's inadequate familiarity with midazolam. Hence, it is imperative not to assume that all medical personnel possess equivalent experience and expertise regarding frequently utilized medications. It is crucial to thoroughly examine prescriptions and processes, especially for common medications, in order to prevent unintentional overdoses. The clinical laboratory, anesthesia, and nursing play crucial roles in

managing patients, including tasks such as identifying drug levels in urine, administering antidotes, performing intubation, and providing more effective therapy with the help of the anesthesia team.

Keywords: *The clinical laboratory, anesthesia, and nursing play crucial roles in managing patients, including tasks such as identifying drug levels in urine, e operator.*

Introduction

The degree of sedation and analgesia that is accomplished is directly proportional to the degree to which sedatives and analgesics tend to impair airway reflexes. According to the judgment of the consultants, this dependence on the level of sedation is reflected as follows: All of them are in agreement that fasting before an operation reduces the hazards associated with moderate sedation, and they are in complete agreement that it reduces the dangers associated with profound sedation. The doctors are in agreement that the target level of sedation should be reduced (that is, less sedative should be delivered) for moderate sedation in emergency cases, when preprocedure fasting is not feasible. However, they are strongly in agreement that the target level of sedation should be modified for deep sedation. It is not possible to evaluate the hypothesis that preprocedure fasting should result in a decreased incidence of bad outcomes in patients who are having either moderate or deep sedation since the literature does not provide adequate data to support this hypothesis [1].

Midazolam is a benzodiazepine that is frequently used for applications such as anesthesia, sedation in patients who are mechanically ventilated, agitated critically sick patients, and patients who have refractory status epilepticus. It is considered to be generally safe. There is a discussion of the hemodynamic effects of this medication in humans in another place [2]. The administration of intravenous midazolam is utilized for the purpose of inducing anesthesia and also for the management of seizures that are acute. Due to the fact that it is water-soluble, midazolam has a rapid beginning of action and can be utilized for the management of status epilepticus in situations when the intravenous administration of other drugs is not practicable. It is possible to raise the dose of midazolam while still maintaining the therapeutic effect because of the high rate of tolerance that it has. It is a promising alternative for the management of seizures in children since it can be administered by the buccal and intranasal routes, which are both simple and straightforward. When compared to thiopental, the response to the induction dose is more variable when it comes to its application in the field of anesthesia. It is possible to utilize midazolam for hypnosis and anxiolysis during the maintenance phase of general anesthesia. Midazolam is also superior to thiopental in the maintenance of anesthesia since it requires less adjunct drugs than thiopental does. The use of midazolam as a drug that is used in conjunction with regional and local anesthetic for a wide variety of diagnostic and therapeutic procedures is becoming increasingly popular among both patients and medical professionals [3].

The oral absorption of midazolam is considered to be poor, and its elimination half-life ranges from 1.5 to 2.5 hours. In the process of conversion, midazolam is transformed into its active metabolite, alpha-1 hydroxy midazolam, which is responsible for 10% of the drug's activity. The hepatic CYP450 enzymes and the glucuronide conjugation process are responsible for the metabolism of midazolam. This is because the mechanism of action of midazolam is indirect, and it is connected to the accumulation of GABA as well as its affinity for the benzodiazepine receptors. Two distinct receptors for GABA and benzodiazepines link to a chloride channel that is shared by each of these receptors. The frequency of chloride channel opening is increased as a result of this. The occupancy of both receptors results in the hyperpolarization of the membrane and the suppression of

neuronal activity. The excess GABA action on motor circuits in the brain is related to the anticonvulsant activity of midazolam, which is a medication used to treat seizures. The muscle-relaxing effect of midazolam is caused by its action on glycine receptors. A significant number of the pharmacologic effects, such as sedation, anxiolysis, anterograde amnesia, and anticonvulsant impact, can be accounted for by the activity of the substance on GABA receptors. It is also possible for the pharmacokinetics of midazolam to be affected by age-related impairments, as well as hepatic and renal insufficiency. The pH of the solution determines whether or not midazolam possesses hydrophilic or lipophilic characteristics [4,5].

Several different methods of administration are available for midazolam, including oral, intranasal, buccal, intravenous, and intramuscular forms. To administer midazolam intravenously, the induction dose ranges from 0.15 to 0.40 mg/kg. This is for the use of midazolam throughout the perioperative period. It is recommended that the premedication be administered intramuscularly at a dose of between 0.07 and 0.10 mg/kg. 0.05 to 0.15 mg/kg is the range that is used to titrate the dose for intravenous sedation. There is a recommended intranasal dose of 0.2 milligrams per kilogram for toddlers aged one to five months. According to the suggestion, the intranasal dose for children aged six months and older should be between 0.2 and 0.3 mg/kg [6].

Review:

Midazolam use is associated with a number of side effects, the most prevalent of which are hiccoughs, coughing, nausea, and vomiting. Other side effects include thrombosis, thrombophilia, and pain that occurs during the injection process. The incidence of thrombophlebitis is comparable to that of thiopental, however it is lower than the rate that occurs with diazepam. The elderly are more likely to experience anterograde amnesia, sleepiness, ataxia, falls, and disorientation when preoccupied with midazolam. It is possible for the midnight injection of midazolam to cause a residual hangover effect, which can impair both cognitive and psychomotor functions. This can lead to falls in elderly people and decreased coordination when driving. A fast intravenous administration may result in the development of hypotension as well as tachycardia. The midazolam infusion syndrome and respiratory depression are also potential outcomes of administering a greater dose. The use of a continuous ventilator is necessary for patients who are experiencing midazolam infusion syndrome. It is possible for persons who have a history of alcohol misuse and aggressive conduct to experience paradoxical effects from midazolam. These symptoms may include involuntary movements, verbalization, uncontrollable sobbing, and aggressive behavior. Even at a dose of 0.15 mg/kg, there is a possibility of experiencing respiratory depression; the risk is increased when the drug is used with fentanyl. Even when administered at therapeutic doses, the use of midazolam in conjunction with other central nervous system depressants can cause severe respiratory depression and even death [7].

Memory problems that are long-lasting and only partially reversible after ceasing the use of midazolam are related with the usage of the medicine for an extended period of time. The administration of the medication during the third trimester of pregnancy induces benzodiazepine withdrawal syndrome in the newborn, which manifests itself as hypotonia, cyanosis, and apneic spells in the newborn. Diarrhea, tremors, and hyperexcitability are all symptoms that may be experienced by newborns. It is estimated that approximately one-third of people who are given midazolam will develop resistance to the medication after using it for a period of four weeks. In the event that the dosage is decreased too quickly, withdrawal symptoms may develop. Irritability, clonus, hypertonicity, nausea, vomiting, diarrhea, tachycardia, and hypertension are some of the symptoms that might occur while a person is withdrawing from benzodiazepines. Suddenly stopping the use of midazolam can lead to a condition known as status epilepticus [8].

Among the conditions that should not be treated with midazolam are acute angle-closure glaucoma, hypotension, and shock. It is vital to make careful adjustments to the dosage in cases of renal and liver problems, as

well as in those who are dependent on alcohol or drugs. Individuals who are pregnant, children, and people who have concomitant psychiatric problems are all required to exercise caution. It is important to use caution while administering the medication to patients who are acutely unwell or old in order to avoid the accumulation of active metabolites. Individuals who are critically ill should be subjected to additional precautions since there is a possibility of dose accumulation [9].

Midazolam is not known to cause toxicity, but it is possible for it to do so when taken with other central nervous system (CNS) depressants such as alcohol, opioids, and other tricyclic antidepressants. It is more likely to occur when the medication is administered intravenously and when the patient is elderly and has COPD. The following are some of the symptoms that can be experienced as a result of an overdose: ataxia, nystagmus, hypotension, slurred speech, decreased motor coordination, coma, and death. In addition, there is a possibility of experiencing reduced reflexes, impaired balance and dizziness, dysarthria, and vasomotor collapse. Midazolam poisoning can be treated with flumazenil that is an antidote. The first step in the therapeutic process is to get supportive treatment. Within one hour of becoming intoxicated, activated charcoal can be used as an alternative. It is not wise to use flumazenil in many situations because it has the potential to cause seizures when combined with other central nervous system depressants in an overdose. The administration of a rapid intravenous infusion to elderly patients who are diagnosed with COPD can also lead to an overdose [10].

As demonstrated in our earlier research, the optimal time for the administration of intramuscular midazolam premedication might be fifteen minutes before to entering the operating room. An intramuscular injection of midazolam results in a fast absorption of the medication from muscle tissue. Within twenty to forty-five minutes of the injection, midazolam achieves its highest levels in the serum. It is important to note that the clinical effects of midazolam do not have a direct correlation with its serum levels. This is due to the fact that the effects are shorter than what would be indicated by its elimination half-life, which is roughly four hours. Therefore, the sedative effects of midazolam begin to manifest themselves within five to ten minutes, reach their peak within thirty to forty minutes, and continue to be sustained for approximately sixty minutes when the medication is delivered correctly [11]. However, there are no studies that have been conducted to far that report on the effects of an overdose of midazolam. The symptoms of an overdose are primarily an increase of the therapeutic effects, and they can result in coma, cardiorespiratory depression, and apnea. On the other hand, the alterations in circulation are quite minor. For many of the cases that were reported in the study, the level of sedation was so high that it was impossible for the patient to respond to verbal contact even two hours after the injection of midazolam. This is a sign of an overdose of midazolam. Both patients, however, did not exhibit any signs of circulatory or respiratory depression, with the exception of the tongue depression that was brought on by the muscle relaxant action of midazolam. This was the case even after the patients had received a fourfold overdose of midazolam. There was no evidence of any inhibition of the respiratory rate of either of the patients when they arrived in the operating room [12]. Because of this, we are able to draw the conclusion that there was no instance of centrally mediated respiratory depression in either of the cases. These findings indicate that there is a wide range of safety associated with intramuscular administration of midazolam. It is possible that individuals who have illnesses of the cardiovascular system, respiratory system, or central nervous system could be at a significant risk during an overdose of midazolam. Fortunately, our instances did not involve any complications. However, even a smaller or comparable dose of midazolam, such as the one that was utilized in this report, was sufficient to cause a patient to pass away after receiving intravenous infusion of midazolam. It is possible that intravenous injection of midazolam poses a greater risk than intramuscular administration [13].

Conclusion:

Midazolam is efficacious when administered promptly during the initiation of seizures induced by nerve agents. Nevertheless, the

efficacy of benzodiazepines in stopping seizures diminishes when administered 30 minutes or more after exposure to organophosphates (OP) or the commencement of the seizure. This is likely due to the internalization or downregulation of synaptic GABAA receptors, rather than extrasynaptic receptors. Consequently, this can result in reduced effectiveness and the possibility of seizure recurrence. The typical side effects linked to the use of midazolam include hiccups, coughing, nausea, and vomiting. Other side effects include thrombophlebitis, thrombosis, and discomfort upon injection. The occurrence of thrombophlebitis is lower with diazepam but comparable to that of thiopental. Midazolam induces anterograde amnesia, somnolence, ataxia, falls, and cognitive disorientation in older individuals. The use of midazolam at night might cause a residual hangover effect, leading to reduced cognitive and psychomotor functions. This can increase the risk of falls in elderly individuals and result in impaired coordination when driving. Rapid intravenous injection might lead to hypotension and tachycardia. Administering a larger amount of midazolam can lead to the occurrence of midazolam infusion syndrome and respiratory depression. Continuous ventilator support is necessary for cases of midazolam infusion syndrome. It is imperative for all healthcare professionals, especially those in clinical laboratory, nursing, and anesthesia departments, to be well-versed in the appropriate actions to take in the case of an overdose. It is necessary to have resuscitative equipment and flumazenil present in the room when administering this medication. The medicine is generally considered safe, although it might potentially lead to respiratory depression, particularly when used in conjunction with fentanyl. The inclusion of physicians, mid-level practitioners, nurses, and pharmacists in interprofessional teamwork will result in improved outcomes for patients by reducing adverse reactions with midazolam. This will be achieved through coordinated monitoring and providing supportive patient counseling.

Reference

[1] Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology. 1985 Mar;62(3):310-24.

[2] Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001905.

[3] Walker M. Status epilepticus: an evidence based guide. BMJ. 2005 Sep 24;331(7518):673-7.

[4] Richter JJ. Current theories about the mechanisms of benzodiazepines and neuroleptic drugs. Anesthesiology. 1981 Jan;54(1):66-72.

[5] Spina SP, Ensom MH. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy. 2007 Mar;27(3):389-98.

[6] Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60.

[7] Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86.

[8] Korttila K, Aromaa U. Venous complications after intravenous injection of diazepam, flunitrazepam, thiopentone and etomidate. Acta Anaesthesiol Scand. 1980 Jun;24(3):227-30.

[9] Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328.

[10] Mencía SB, López-Herce JC, Freddi N. Analgesia and sedation in children: practical approach for the most frequent situations. J Pediatr (Rio J). 2007 May;83(2 Suppl):S71-82.

[11] McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994 Nov-Dec;8(6):461-75.

[12] Suri Y. EVALUATION OF MIDAZOLAM AND DIAZEPAM FOR PRE-OPERATIVE SEDATION. Med J

Armed Forces India. 2000 Oct;56(4):287-292.

[13] Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61.